The EVUSHELD Access Program:
The Virginia Department of Health developed the EVUSHELD Access Program to support Skilled Nursing Facilities with COVID-19 infection prevention by increasing access to EVUSHELD, a monoclonal antibody for COVID-19 pre-exposure prophylaxis. The program provides access to EVUSHELD via a mobile unit and VDH staff are available to support interested facilities in coordinating a site-visit. The program is free of charge for facilities and eligible nursing home patients and staff.

How to participate in the program:
Please reach out to COVID19Therapeutics@vdh.virginia.gov to request an appointment.

Eligibility:
EVUSHELD is a COVID-19 protective measure for adults who:

- Are not currently infected with the SARS-CoV-2 virus and not recently exposed to an individual infected with SARS-CoV-2, AND
- Have moderate to severely compromised immune systems due to a medical condition or taking immunosuppressive medications and may not mount an adequate immune response to COVID-19 vaccination, OR
- Have a history of severe adverse reactions to a COVID-19 vaccine and/or component(s) of those vaccines, therefore vaccination with an available COVID-19 vaccine is not recommended

Billing
There is no cost for Nursing Homes to participate in this program.

- Patient(s) covered by Medicare/Medicaid: Post treatment administration, the mobile vendor will bill Medicare/Medicaid for administration reimbursement.
- Patient(s) NOT covered by Medicare/Medicaid: Post treatment administration, the contractor will bill the VDH Central Office for all patients not covered under Medicare/Medicaid.

Components

<table>
<thead>
<tr>
<th>Administration</th>
<th>1 vial of Tixagevimab 300 mg/3.0 mL (100 mg/mL) (dark grey cap)</th>
<th>1 vial of Cilgavimab 300 mg/3.0 mL (100 mg/mL) (white cap)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Administered as two consecutive intramuscular (IM) injections in the gluteal muscles. Repeat dose is recommended every 6 months.</td>
<td>NDC 0310-8895-01</td>
<td>NDC 0310-1061-01</td>
</tr>
</tbody>
</table>

*Patients who received the previously recommended dosage of 150 mg of tixagevimab and 150 mg of cilgavimab should receive an additional dosage of 150 mg of tixagevimab and 150 mg of cilgavimab as soon as possible.

To access the most recent EVUSHELD Fact Sheets, please scan the QR code provided below.

http://www.evusheld.com Updated July 2022